Go Pro
NASDAQ:HYPD

Hyperion DeFi Q1 2025 Earnings Report

Hyperion DeFi logo
$3.26 +0.15 (+4.82%)
Closing price 04:00 PM Eastern
Extended Trading
$3.28 +0.02 (+0.46%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Hyperion DeFi EPS Results

Actual EPS
-$1.59
Consensus EPS
-$7.20
Beat/Miss
Beat by +$5.61
One Year Ago EPS
N/A

Hyperion DeFi Revenue Results

Actual Revenue
$1.60 million
Expected Revenue
$1.60 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Hyperion DeFi Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Sunday, May 18, 2025
Conference Call Time
6:00PM ET

Hyperion DeFi Earnings Headlines

Hyperion Gains on Blockdaemon Hookup
4th of July Chaikin flash sale
Marc Chaikin - the 60-year Wall Street veteran who called Nvidia before it surged 45,000% - is running his first-ever 4th of July flash sale through July 6th only. His Power Gauge Report membership comes with a free year of access to his Power Gauge Rating system, a 100% money-back guarantee, and a Hotlist of buy and sell ideas - including a little-known Nvidia partner he calls 'an upgrade to Tesla stock' in the autonomous vehicle race. His tools are used on Bloomberg and Reuters terminals worldwide and have helped investors grow assets by as much as 69,000%.tc pixel
See More Hyperion DeFi Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hyperion DeFi? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hyperion DeFi and other key companies, straight to your email.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

View Hyperion DeFi Profile